Buprenorphine MAT as an Imperfect Fix

Expanding buprenorphine access in the United States requires evidence-based decision-making that considers both the drug's potential dangers and its potential benefits. Risks associated with buprenorphine misuse and diversion highlight the need for careful, ongoing evaluation during each stage of increased access.

[1]  Unite Evaluations.  UNITED NATIONS OFFICE ON DRUGS AND CRIME-INDEPENDENT EVALUATION SECTION , 2020 .

[2]  Statement from FDA Commissioner Scott Gottlieb, M.D. on steps toward a new, tailored review framework for artificial intelligence-based medical devices , 2019, Case Medical Research.

[3]  Bethany J Figg,et al.  Substance Abuse and Mental Health Services Administration , 2018, Journal of Consumer Health on the Internet.

[4]  M. Barnes,et al.  Physician Autonomy and the Opioid Crisis , 2018, Journal of Law, Medicine & Ethics.

[5]  M. Kamdar,et al.  Dreamland: The True Tale of America's Opiate Epidemic. , 2018, Journal of Palliative Medicine.

[6]  B. Hoeppner,et al.  Prevalence and pathways of recovery from drug and alcohol problems in the United States population: Implications for practice, research, and policy. , 2017, Drug and alcohol dependence.

[7]  K. Carroll,et al.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. , 2017, The American journal of psychiatry.

[8]  J. Havens,et al.  Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. , 2017, Drug and alcohol dependence.

[9]  Gary A. Smith,et al.  Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000–2015 , 2017, Pediatrics.

[10]  M. Faul,et al.  Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies — United States, 2007–2014 , 2017, MMWR. Morbidity and mortality weekly report.

[11]  G. Dunn,et al.  Impact of treatment for opioid dependence on fatal drug‐related poisoning: a national cohort study in England , 2015, Addiction.

[12]  Master Textbook.  TIP 43: Medication-Assisted Treatment For Opioid Addiction in Opioid Treatment Programs , 2016 .

[13]  I. Khanna,et al.  Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain , 2015, Journal of pain research.

[14]  Shana Harris.  To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine. , 2015, Medical anthropology quarterly.

[15]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[16]  S. Walsh,et al.  A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World , 2014, Journal of addiction medicine.

[17]  W. Ling,et al.  Medication-assisted treatment for opioid addiction: methadone and buprenorphine. , 2013, Journal of food and drug analysis.

[18]  G. Badger,et al.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. , 2013, JAMA psychiatry.

[19]  K. Lyseng-Williamson.  Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA , 2013 .

[20]  D. Basu,et al.  Buprenorphine-induced psychotic symptoms: a case report. , 2013, The primary care companion for CNS disorders.

[21]  Kaarlo Simojoki,et al.  A Five-Year Follow-up of Buprenorphine Abuse Potential , 2013 .

[22]  J. Tiihonen,et al.  Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. , 2013, Drug and alcohol dependence.

[23]  R. Sedefov,et al.  Misuse of Medicines in the European Union: A Systematic Review of the Literature , 2012, European Addiction Research.

[24]  J. Maxwell.  The prescription drug epidemic in the United States: a perfect storm. , 2011, Drug and alcohol review.

[25]  A. Melinder,et al.  Prenatal exposure to methadone and buprenorphine: A review of the potential effects on cognitive development , 2011, Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence.

[26]  J. Rich,et al.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. , 2011, Current drug abuse reviews.

[27]  B. Clin,et al.  Fatal poisoning due to snorting buprenorphine and alcohol consumption. , 2011, Forensic science international.

[28]  R. Schottenfeld,et al.  Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. , 2010, Drug and alcohol dependence.

[29]  R. Blondell,et al.  A Clinical Trial Comparing Tapering Doses of Buprenorphine With Steady Doses for Chronic Pain and Coexistent Opioid Addiction , 2010, Journal of addiction medicine.

[30]  D. Celentano,et al.  The Profile of Injection Drug Users in Chennai, India: Identification of Risk Behaviours and Implications for Interventions , 2010, Substance use & misuse.

[31]  Jeffrey J. Annon,et al.  Buprenorphine tapering schedule and illicit opioid use. , 2009, Addiction.

[32]  Kaarlo Simojoki,et al.  Substance Abuse Treatment, Prevention, and Policy a Retrospective Evaluation of Patients Switched from Buprenorphine (subutex) to the Buprenorphine/naloxone Combination (suboxone) , 2007 .

[33]  E. Vuori,et al.  Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. , 2007, Drug and alcohol dependence.

[34]  L. Manchikanti.  Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. , 2006, Pain physician.

[35]  Jean Larch,et al.  Dying to Be Free , 2005 .

[36]  M. Soyka,et al.  Less Impairment on One Portion of a Driving-Relevant Psychomotor Battery in Buprenorphine-Maintained Than in Methadone-Maintained Patients: Results of a Randomized Clinical Trial , 2005, Journal of clinical psychopharmacology.

[37]  J. Rehm,et al.  Eyes Wide Shut? – A Conceptual and Empirical Critique of Methadone Maintenance Treatment , 2004, European Addiction Research.

[38]  Airi Partanen,et al.  Buprenorphine more common as a problem drug in Finland , 2004 .

[39]  J. Ahmadi,et al.  Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study , 2003, European journal of clinical investigation.

[40]  J. Jaffe,et al.  From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. , 2003, Drug and alcohol dependence.

[41]  Jason M. White,et al.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. , 2003, Addiction.

[42]  T. George,et al.  The Neurobiology of Opioid Dependence: Implications for Treatment , 2002, Science & practice perspectives.

[43]  R M Bell,et al.  Simultaneous polydrug use among teens: prevalence and predictors. , 1998, Journal of substance abuse.

[44]  R. Brooner,et al.  Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. , 1997, Archives of general psychiatry.

[45]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[46]  S. Saxena,et al.  Naloxone-induced withdrawal in patients with buprenorphine dependence. , 1994, Addiction.

[47]  P. Cushman.  Alcohol and opioids: possible interactions of clinical importance. , 2008, Advances in alcohol & substance abuse.

[48]  M. Rosenbaum,et al.  Not the picture of health: women on methadone. , 1987, Journal of psychoactive drugs.